Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 11:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 133 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Investigational CT Scan Clear all
Completed Phase 3 Interventional Results available

Study of Diagnostic Performance of [18F]CTT1057 in BCR

NCT04838613
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer, Recurrence
Interventions
[18F]CTT1057, [68Ga]Ga-PSMA-11
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 7, 2026, 11:45 PM EDT
Active, not recruiting Early Phase 1 Interventional

Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy

NCT05160597
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Biopsy of Prostate, Gallium Ga 68 Gozetotide, Transrectal Ultrasonography Guided Biopsy
Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Phase 2 Interventional

An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma

NCT06521775
View directory record Official record
Conditions
Metastatic Adenoid Cystic Carcinoma
Interventions
Computed Tomography, Electronic Health Record Review, Ga-68 PSMA-11, Positron Emission Tomography
Procedure · Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Not applicable Interventional Results available

Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients

NCT00606294
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
fluorine-18-labeled fluoro-misonidazole (18F-FMISO), 18F-FMISO PET scan, MRI, FDG PET/CT scan
Radiation · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2023
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 7, 2026, 11:45 PM EDT
Not listed Early Phase 1 Interventional

PET-CT vs. Integrated MR-PET Scanning of GYN Cancers

NCT01779128
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Ovarian Cancer
Interventions
PET-CT, MR-PET
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Sep 7, 2026, 11:45 PM EDT
Terminated Not applicable Interventional

Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability

NCT01241942
View directory record Official record
Conditions
Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
Interventions
Steen Solution™, Conventional Lung Transplant
Device · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Phase 4 Interventional

Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease

NCT02476526
View directory record Official record
Conditions
Chronic Kidney Disease, Pulmonary Embolism, Renal Artery Stenosis, Pulmonary Cancer
Interventions
Low Volume iso-osmolar non-ionic radio contrast medium, Acetylcysteine Inhalation, Sodium Bicarbonate Solution, 64-MDCT Scanning
Drug · Procedure
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2017 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Early Phase 1 Interventional

C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate Cancer

NCT02715583
View directory record Official record
Conditions
Prostate Cancer Patients
Interventions
11C-Acetate
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Phase 2 Interventional Results available

Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma

NCT03318497
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT, Computed Tomography, Positron Emission Tomography, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 7, 2026, 11:45 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Single-tracer Multiparametric PET Imaging

NCT06014515
View directory record Official record
Conditions
Healthy Subjects, Cardiovascular Disease
Interventions
18F-FDG, 11C-butanol
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2033
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 7, 2026, 11:45 PM EDT
Suspended Phase 2 Interventional

Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer

NCT04346225
View directory record Official record
Conditions
Prostate Cancer, Advanced Prostate Carcinoma
Interventions
Hyperpolarized C13, Magnetic Resonance Imaging (MRI)
Drug · Procedure
Lead sponsor
Ivan de Kouchkovsky, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Not applicable Interventional

The Feasibility of Using Anesthesia and Suspended Ventilation to Immobilize Liver Tumors During Radiotherapy

NCT00774501
View directory record Official record
Conditions
Liver Cancer
Interventions
image guidance with general anesthesia and suspended ventilation during treatment delivery
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Evaluation for General Electric (GE) CT System

NCT01909180
View directory record Official record
Conditions
CT Scanners X Ray
Interventions
Revolution CT Scanner
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Phase 1 Interventional Results available

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

NCT02595866
View directory record Official record
Conditions
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
Interventions
Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 7, 2026, 11:45 PM EDT
Completed No phase listed Observational

Clinical Data Collection and Evaluation of ECG-Less Cardiac CT

NCT05949138
View directory record Official record
Conditions
Cardiac CT
Interventions
ECG-Less Cardiac CT using SmartPhase
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
2
States / cities
Chicago, Illinois • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611

NCT02509507
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Metastases, Cutaneous or Subcutaneous Lymph Node, Liver Tumors
Interventions
Talimogene Laherparepvec, Pembrolizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
9
States / cities
Scottsdale, Arizona • Santa Monica, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Not applicable Interventional Results available

Translational Development of Photon-counting CT Imaging

NCT03878134
View directory record Official record
Conditions
Cancer, Inflammatory Disease, Vascular Diseases, Metabolic Bone Disease
Interventions
PHOTON COUNTING CT Scanner
Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Phase 2 Interventional Results available

FACBC PET/CT for Recurrent Prostate Cancer

NCT00562315
View directory record Official record
Conditions
Prostate Cancer
Interventions
FACBC, ProstaScinct
Drug · Other
Lead sponsor
David M. Schuster, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Sep 7, 2026, 11:45 PM EDT
Enrolling by invitation Not applicable Interventional

Study to Determine the Clinical Significance of Intravascular OCT-NIRAF

NCT06374498
View directory record Official record
Conditions
Cardiovascular Diseases, Coronary Artery Disease
Interventions
OCT-NIRAF, LUMISIGHT Injection, OCT-NIRAF following LUMISIGHT Injection
Device · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 7, 2026, 11:45 PM EDT
Completed No phase listed Observational

Non-Invasive Cerenkov Luminescence Imaging of Lymphoma, Leukemia and Metastatic Lymph Nodes

NCT01664936
View directory record Official record
Conditions
Head and Neck Cancers
Interventions
Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Phase 3 Interventional Results available

Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer

NCT02260817
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
11C-choline Injection
Drug
Lead sponsor
Global Isotopes, LLC d/b/a Zevacor Molecular
Industry
Eligibility
18 Years and older · Male only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Decatur, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 7, 2026, 11:45 PM EDT
Terminated No phase listed Observational

PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning

NCT03286972
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
PET/MRI
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Sep 7, 2026, 11:45 PM EDT
Withdrawn Phase 2 Interventional

Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes

NCT06973109
View directory record Official record
Conditions
Osteoporosis, Post-menopausal
Interventions
Romosozumab, Alendronate (Fosamax), Placebo Romosozumab, Placebo Alendronate
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 7, 2026, 11:45 PM EDT
Enrolling by invitation Not applicable Interventional

Pilot Evaluation of the StarGuide Next Generation SPECT/CT System

NCT07272161
View directory record Official record
Conditions
Nuclear Medicine
Interventions
StarGuide NextGen SPECT/CT system
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 7, 2026, 11:45 PM EDT